Address: Breitenfurter Str. 113, Top 101, 1120 Vienna,Austria
Tel: + 43 1 595 3960
Web: http://www.almirall.com/webcorp2/cda/index.jsp
Almirall is an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain.
In Almirall we research, develop, produce and market proprietary R&D medicines and those under licence with the aim of improving people’s health and wellbeing.
We devote big human and economic resources to constant research into new drugs and to obtaining effective and safe products against discomfort and disease.
The therapeutic areas on which we focus our research resources are related to the treatment of:
AsthmaCOPD (Chronic Obstructive Pulmonary Disease)
Gastrointestinal disorders
Psoriasis
Other dermatological conditions
To achieve these objectives, we work tirelessly to reinforce a corporate culture based on professionalism and teamwork.
Our medicines are present in over 70 countries, with a direct presence in Europe and Latin America. Our objective is to help thousands of people around the world stay healthy.
Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today?…
Barbara Fritsche-Surchat, general manager of Servier Austria, a leading innovative French company looking to bolster its global oncology presence, provides an in-depth analysis of the balancing act between pricing and…
Martin Spatz, country manager of QuintilesIMS Austria, the global leader in healthcare market research, discusses the diverse range of services they provide to the two separate entities of the of…
Rudolf Wessely, CEO and founder of Gynial, the Austrian leader in oral contraceptives, elaborates on the company’s incredibly fast market penetration since 2007 and explains his expertise in the contraceptive…
Bernhard Wittmann, managing director of Sigmapharm and MoNo, discusses the company’s product portfolio and the diverse tailored services for their partners. Furthermore, he provides an in-depth look into MoNo’s new…
Martin Tiani, CEO of Tiani Spirit, the global leader in Integrating the Healthcare Enterprise (IHE), discusses the importance of interoperability within electronic health information exchange (HIE) and the challenges e-health faces, especially…
Dr. Dietmar Katinger, CEO of Polymun, an Austrian R&D and contract manufacturing company, discusses the challenges CMO companies face within the Austrian market and increasing industry regulations. He also provides…
Like a family recipe that has been refined and perfected over countless generations, Austria has developed a reputation as the quintessential clinical trials destination; a perfect combination of world-class academia,…
Dr. Kurt Zatloukal, national node director of the Bio-Banking and Bio-Molecular Resources Research Infrastructure of Austria (BBMRI Austria), discusses the challenges of collaboration between the private and academic pharmaceutical sectors…
Dr. Daniel Wallerstorfer, CEO and founder of Novogenia, a vibrant Austrian genetics company, discusses founding his own company and the innovative services Novogenia provides to ensure genetics are a staple…
Günther Aschenbrenner, managing director of Théa Austria, a specialist French ophthalmology company, discusses the development of the company’s Austrian office since 2011 and how a strong portfolio acquired by Théa…
Daniela Homan, executive director of AmCham Austria, the representative and advocating voice of US companies in Austria, provides an in-depth analysis of the strategies being employed by the chamber and…
Karl Peter Schwarz, general manager of the Austrian affiliate of LEO Pharma, an ambitious Danish company leading the way in innovative dermatology treatments, provides an in-depth look into how global…
See our Cookie Privacy Policy Here
